The Effect of Changes in Tumor Size on Breast Carcinoma Survival in the U.S.:
|
|
- George Goodwin
- 5 years ago
- Views:
Transcription
1 1149 The Effect of Changes in Tumor Size on Breast Carcinoma Survival in the U.S.: Elena B. Elkin, Ph.D. 1 Clifford Hudis, M.D. 2 Colin B. Begg, Ph.D. 1 Deborah Schrag, M.D., M.P.H. 1,2 1 Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan- Kettering Cancer Center, New York, New York. 2 Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York. BACKGROUND. Temporal comparisons of case survival are commonly used to assess improvement in cancer treatment at the population level. However, such comparisons may be confounded by secular trends in disease prognosis, even within conventional stage categories. The objective of the current study was to characterize within-stage migration of tumor size in breast carcinoma, and to estimate the effect of this shift on reported breast carcinoma survival. METHODS. Population-based Surveillance, Epidemiology, and End Results (SEER) cancer registry data were used to evaluate secular trends in tumor size at the time of diagnosis and relative survival among localized and regional invasive breast carcinoma patients diagnosed between Outcomes were stage-specific tumor size distribution, 5-year relative survival, relative survival standardized to the tumor size distribution of the cohort diagnosed between , and the percentage of improvement in relative survival attributable to shifts in tumor size distribution. RESULTS. Within each stage category, the proportion of smaller tumors increased significantly over time. Comparing patients diagnosed between with those diagnosed between , within-stage migration of tumor size accounted for 61% and 28%, respectively, of the relative survival increases noted in localized and regional breast carcinoma. CONCLUSIONS. The tumor size distribution of incident breast carcinomas in SEER has shifted toward smaller tumors. A substantial fraction of the improvement in breast carcinoma survival noted since 1975 may be attributable to within-stage migration of tumor size. Cancer 2005;104: American Cancer Society. Presented in part at the 40th Annual Meeting of the American Society for Clinical Oncology, New Orleans, Louisiana, June 5 8, The authors gratefully acknowledge Lynn Ries, Kathleen Cronin, Eric Feuer, and the Surveillance, Epidemiology, and End Results (SEER) Program for providing extent-of-disease data for breast carcinoma cases in SEER diagnosed prior to 1988, for supplying the historic coding manuals necessary to interpret these data, and for offering helpful comments on a draft of this article. Address for reprints: Elena B. Elkin, Ph.D., Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., Box 44, New York, NY 10021; Fax: (646) ; elkine@mskcc.org Received February 14, 2005; revision received April 15, 2005; accepted April 26, KEYWORDS: breast carcinoma, survival, relative survival, tumor size, trends. Breast carcinoma mortality has declined substantially over the past 30 years, from 31.4 deaths per 100,000 women per year in 1975 to 25.9 deaths per 100,000 women per year in Because the mortality rate depends on both the incidence of newly diagnosed tumors and the death rate of women diagnosed with the disease, and the incidence of breast carcinoma has increased considerably since 1975, 1 the decline in breast carcinoma mortality necessarily implies an improved survival rate among diagnosed patients. Indeed, population-based cancer registry data document improvements in breast carcinoma survival over time, both across and within disease stage categories. 1,2 The secular trend toward better breast carcinoma survival in the U.S. has coincided with important advances in both screening and treatment. The first national guidelines recommending populationwide mammography screening were issued in the late 1970s, 3 and the use of screening increased dramatically in subsequent decades. 4 Dur American Cancer Society DOI /cncr Published online 8 August 2005 in Wiley InterScience (
2 1150 CANCER September 15, 2005 / Volume 104 / Number 6 ing this same time period, the effectiveness of cytotoxic and hormonal systemic agents was established in both the adjuvant and metastatic settings, 5 7 and their use has increased considerably. 8 Ultimately the goal of both screening and treatment is the same to reduce mortality from the disease but distinguishing the relative contributions of these two modalities is difficult. The impact of screening can be assessed only on the basis of mortality rates in the screened population. 9 Case survival cannot be used for this purpose because the date of diagnosis, the time origin for calculating survival, is advanced by an unknown time interval due to a screening test even if the test has no beneficial impact on mortality. Independent of the true benefits of screening, screendetected tumors will always have longer survival times than symptom-detected tumors because the diagnosis is made earlier in the natural history of the disease, a phenomenon known as lead time bias Although the impact of screening must be evaluated using mortality rates in the population at risk for breast carcinoma, the impact of treatment is assessed more directly by studying changes in case survival because cases represent the population to which treatment is applied. For this purpose, changes in survival, or relative survival, have been used to monitor secular trends in the U.S. and elsewhere. 2,13 17 However, temporal comparisons of this nature rely on the assumption that the inherent composition of diagnosed cases with respect to prognosis does not change over time, or that such changes can be suitably controlled by stratification on the basis of stage of disease. Even within conventional stage categories, the distribution of important prognostic characteristics may change over time. Although a number of factors affect disease outcome, tumor size is an obvious marker of natural history and a strong predictor of breast carcinoma survival Tumor size also is a straightforward, reliably evaluated, consistently available metric. The Surveillance, Epidemiology, and End Results (SEER) Program, which tracks trends in cancer incidence and survival in the U.S., has collected detailed information regarding the size of newly diagnosed breast tumors since The objective of the current study was to assess the impact of within-stage migration of tumor size on changes over time in breast carcinoma survival. We characterized the tumor size distribution of localized and regional breast carcinomas diagnosed between to document the extent of within-stage migration of tumor size. We then used this information to determine the percentage of improvement in relative survival that could be attributable to shifts in the tumor size distribution. Our goal was to provide a more accurate estimate of the impact of the evolution of breast carcinoma treatment on survival. MATERIALS AND METHODS Data The current study sample was comprised of nonmetastatic, invasive breast carcinoma cases reported to the SEER cancer registries between We used data from the nine registries that have been included in SEER since its inception in Together, these registries cover geographic regions representing approximately 10% of the U.S. population. The registries collect clinical and sociodemographic data concerning all incident cancers in their coverage area, with active follow-up for date and cause of death. The SEER registries maintain high standards of data quality, and the program s overall completeness of case ascertainment is reported to be 98%. 22 We included first primary invasive breast tumors designated as localized or regional. Stage at diagnosis was based on the SEER historic staging system in which localized tumors are those tumors entirely confined to the breast, and regional tumors are those tumors with extension beyond the breast into surrounding tissues or axillary lymph nodes. 23 Cases for which stage information was missing ( 3%) were excluded. We also excluded localized tumors with axillary lymph node involvement recorded as positive ( 1% of cases), assuming that either their stage or lymph node status was misclassified. Although the staging system developed by the American Joint Committee on Cancer (AJCC) stratifies tumors more precisely according to specific categories of tumor size, lymph node involvement, and distant metastases, AJCC stage was not recorded by SEER until 1988, and data limitations for tumors diagnosed between prevented us from assigning AJCC stage designations to these cases. Because our analysis focused on shifts in the tumor size distribution within stage categories, we evaluated localized and regional tumors separately. These two stages constitute approximately 92% of the invasive breast carcinomas with known stage in SEER. We did not study women who presented with distant metastases at the time of diagnosis because the extent of local disease is largely unrelated to prognosis in those cases. Tumors diagnosed only at the time of death also were excluded. In the SEER public-use files, detailed extent-ofdisease information (i.e., tumor size, tumor extension, and lymph node involvement) is available only for cases diagnosed since We obtained additional SEER data from the National Cancer Institute and
3 Tumor Size and Breast Ca Survival/Elkin et al TABLE 1 SEER Extent-of-Disease Variables Tumor size Lymph nodes EOD: extent of disease. Year of diagnosis Expanded EOD-CP53 Expanded EOD- CP54 Expanded EOD-CP59 Expanded EOD- CP60 EOD4-size EOD4- lymph nodes EOD10-size EOD10- lymph nodes reviewed the relevant coding manuals to identify tumor size for cases diagnosed prior to Specific variables used in the analysis are listed in Table 1. Tumor Size Classification Since 1975, three different coding schemes have been used in SEER to classify tumor size. In all years, size was recorded as the maximum dimension of the primary tumor. Between , two measurements of tumor size were recorded: the size given in the pathology or surgical report and the size noted at the time of clinical examination. For both measurements, SEER used 11 different size categories. For the current analysis, we used the size recorded in SEER from the pathology or surgical report if available, and the size noted on the clinical examination if not. Since 1983, only one tumor size measurement has been recorded, but the SEER registrars prioritize the size listed in the pathology report, the surgical report, and the physical examination in that order. Size is recorded in millimeters, with tumors measuring less than 3 mm combined into 1 category. Between , tumors measuring 10.0 cm and larger were combined. Since 1988, exact tumor size has been specified up to 99.0 cm. In all years, diffuse or inflammatory disease is identified as a distinct category. We integrated the three coding schemes to group tumor size into clinically meaningful intervals while maintaining a consistent definition across time periods. The resulting tumor size categories for the current analysis were: 1.0 cm, cm, cm, cm, cm, 5.0 cm, and size not stated. Tumors with microscopic focus or foci and those described as mammographically detected, nonpalpable tumors were classified as measuring 1.0 cm. Tumors described as diffuse or inflammatory were grouped with those tumors measuring 5.0 cm. Cases of Paget disease of the nipple and carcinomas in which the tumor size was reported as no tumor were excluded from the analysis; these tumors constituted fewer than 1% of all cases in each time period. Relative Survival Year of diagnosis was grouped into 5-year intervals: , , , , and Follow-up for vital status was available through 2001, the study cutoff point for survival analysis. For the cohort of cases in each time period, crude 5-year relative survival was calculated as the ratio between the overall survival probability observed in the breast carcinoma cohort and the survival probability expected in the absence of breast carcinoma. 24 Relative survival probabilities and standard errors were estimated using SEER*Stat (SEER*Stat, version 5.2.2; Information Management Services Inc., Silver Spring, MD), a software package developed specifically for the analysis of SEER data. SEER*Stat generates expected survival probabilities from U.S. population statistics, matched to SEER cases by race (white, black, American Indian, Chinese, Japanese, Filipino, Hawaiian, Puerto Rican, or Hispanic), gender, age (by year), and the date at which age was coded. 25 Cases with race described as other or unknown were excluded from relative survival calculations. Tumor Size Standardized Relative Survival To standardize relative survival to the tumor size distribution of the cohort, we first calculated tumor size-specific relative survival probabilities within each cohort. The tumor size-standardized relative survival for each cohort was then estimated by calculating a weighted average of these relative survival probabilities across tumor sizes, in which the weights for each tumor size category were based on the tumor size distribution of the cohort. For each of the later cohorts, this yielded a size-standardized relative survival estimate, with the cohort serving as the standard population. This method of direct standardization is commonly used in epidemiologic research to age-adjust rates of disease incidence and mortality. 26 Survival analysis and tumor size standardization were performed separately for localized and regional breast carcinoma. We also repeated the analysis, within each disease stage, stratified by age group (ages yrs, ages yrs, and age 65 yrs). Statistical Analysis Changes in the within-stage tumor size distributions were assessed using the Cochran Armitage test for trend. 27,28 Time trends were considered significant if the test statistic had a two-sided P value of less than 0.05.
4 1152 CANCER September 15, 2005 / Volume 104 / Number 6 FIGURE 1. Tumor size distribution of localized breast carcinomas diagnosed in the Surveillance, Epidemiology, and End Results (SEER) program, NS: tumor size not stated. To estimate increases in relative survival over time, we compared each cohort with the cohort. We calculated the change in crude relative survival as well as the change in size-standardized relative survival. The percent of change in relative survival explained by a shift in the tumor size distribution is shown by the following formula: % change explained by tumor size shift, cohort i 1 R St R 75 R i R in which R i is crude relative survival in the i th cohort, R St is size-standardized relative survival, and R 75 is relative survival in the cohort. Other than the estimation of relative survival, calculations and statistical analyses were performed using Excel (Microsoft Corporation, Redmond, WA) and SAS (SAS version 9.0; SAS Institute Inc., Cary, NC) software. RESULTS Tumor Size The sizes of incident invasive breast tumors in SEER have decreased substantially since The magnitude of this change is shown in Figure 1 for localized breast carcinoma and Figure 2 for regional breast carcinoma. Among localized breast carcinomas (n 166,317), fewer than 10% of tumors diagnosed between measured 1cm, whereas 25% of tumors diagnosed between measured 1cm. Among regional breast carcinomas (n 99,522), the proportion of tumors measuring 2cm increased from approximately 20% in the cohort to 33% in the cohort. In both localized and regional breast carcinoma cases, the secular trend toward an increasing proportion of smaller tumors was found to be statistically significant (P ). Crude Relative Survival In localized breast carcinoma, crude relative survival increased from 90.7% in the cohort to 97.4% in the cohort (Table 2). Despite this substantial increase, tumor size-specific 5-year relative survival changed by much smaller amounts during the 25-year period. The greatest absolute change occurred among tumors measuring cm, with relative survival increasing from 94.5% in the cohort to 99.9% in the cohort. For other size categories, the changes were small to nonexistent. Absolute survival improvements were somewhat greater among regional breast carcinomas (Table 3), with crude relative survival increasing from 67.8% to 79.6% over the 25- year period. The greatest absolute relative survival
5 Tumor Size and Breast Ca Survival/Elkin et al FIGURE 2. Tumor size distribution of regional breast carcinomas diagnosed in the Surveillance, Epidemiology, and End Results (SEER) program, NS: tumor size not stated. TABLE 2 5 Year Relative Survival (%) in Patients with Localized Breast Carcinoma Year of diagnosis No ,089 22,900 34,630 41,714 47,984 Absolute change a Crude RS (SE) 90.7 (0.6) 91.5 (0.6) 95.4 (0.4) 96.8 (0.4) 97.4 (0.5) 6.7 Tumor size-specific RS 1 cm b b b cm cm cm cm cm Size not stated Size-standardized RS RS: relative survival; SE: standard error. a Absolute change reflects a comparison between the cohort diagnosed between and the cohort diagnosed between b The relative survival rate was adjusted to because the observed survival rate in the cohort exceeded the expected survival rate. increases were noted in tumors measuring 1cm and tumors measuring 5 cm. Size-Standardized Relative Survival Both crude 5-year relative survival and tumor sizestandardized relative survival increased between 1975 and However, as shown in Tables 2 and 3, standardization on the basis of tumor size attenuated the magnitude of this increase. Comparing the earliest ( ) and most recent ( ) cohorts, the size-standardized relative survival for localized breast tumors increased from 90.7% to only 93.3%, versus 97.4% without standardization; therefore size standardization accounted for 61% of the apparent improvement in 5-year relative survival among localized breast tumors. Size-standardization explained 28% of the apparent improvement in relative survival observed among regional breast tumors.
6 1154 CANCER September 15, 2005 / Volume 104 / Number 6 TABLE 3 5-Year Relative Survival (%) in Patients with Regional Breast Carcinoma No. Year of diagnosis ,388 19,815 21,021 19,833 21,465 Absolute change a Crude RS (SE) 67.8 (0.8) 70.9 (0.8) 74.4 (0.7) 77.4 (0.7) 79.6 (1.0) 11.8 Tumor size-specific RS 1 cm cm cm cm cm cm Size not stated Size standardized RS RS: relative survival; SE: standard error. a The absolute change reflects the comparison between the cohort diagnosed between and the cohort diagnosed between TABLE 4 Crude and Size-Standardized 5-Year Relative Survival (%) by Patient Age at Diagnosis Localized breast carcinoma years years Regional breast carcinoma > 65 years years years > 65 years Crude RS cohort cohort Difference Size-standardized RS cohort cohort Difference % explained by size shift 38% 52% 96% 23% 22% 44% RS: relative survival. Stratification by Age Among both localized and regional breast carcinomas, the proportion of survival improvement that was attributable to within-stage migration of tumor size was found to be greater for older patients (Table 4). In localized breast carcinoma cases, tumor size standardization explained 38%, 52%, and 96% of the observed improvement in relative survival among women ages years, years, and 65 years and older, respectively. In regional breast carcinoma cases, tumor size standardization explained twice the proportion of survival benefit in women age 65 and older (44%) compared with women ages years (23%) and years (22%). DISCUSSION In this analysis, we used a population-based data source to describe changes over time in the distribution of tumor size among incident breast carcinomas. The literature regarding screening mammography has demonstrated that screening causes a shift toward earlier stage disease, primarily through the detection of smaller tumors The results of the current study characterize the extent to which the tumor size distribution has shifted, even within stage categories. These results also demonstrate that failure to adequately control for this shift leads to inflated estimates of the impact of secular changes in treatment on stage-specific survival. A substantial proportion of the observed improvement in stage-specific breast carcinoma sur-
7 Tumor Size and Breast Ca Survival/Elkin et al vival over the past 30 years can be attributed to this within-stage migration of tumor size. Standardization of survival rates in contemporary cohorts to the tumor size distribution of women diagnosed between was found to explain 61% of the observed survival improvement in localized breast carcinoma and 28% of the improvement in regional breast carcinoma over the past 25 years. We believe that size standardization is a refinement of relative survival that greatly improves our ability to interpret secular trends in breast carcinoma survival. We used relative survival as an indicator of disease outcome because it is a preferred measure of cancer survival. 35 However, changes in relative survival over time may be influenced by secular changes in important causes of death other than cancer. This is controlled to some degree by the use of expected survival rates that correspond with each cancer patient s date of diagnosis. Relative survival estimates also may be problematic if expected survival in the cohort of interest is not representative of the general population, even after matching based on age, gender, race, and date. This could be the case if women with screendiagnosed early-stage breast carcinoma are healthier on average than their unscreened peers. Therefore, changes in relative survival, even after tumor size adjustment, cannot be considered a definitive measure of the impact of treatment. In addition, adjustment of relative survival estimates using the traditional method of direct standardization has been criticized as conceptually inconsistent because crude and adjusted relative survival probabilities may not be equal in the standard population. 36,37 In patients with localized and regional breast carcinoma who were diagnosed between (the standard population in the current analysis) crude and tumor size-adjusted relative survival were nearly identical (data not shown), suggesting that the potential limitations of direct standardization do not substantially threaten the validity of the current findings. Moreover, we repeated all analyses using disease-specific survival as the primary outcome, and the results were similar to those based on relative survival. However, disease-specific survival is also not a definitive metric because cause-of-death attribution is subject to a variety of biases and errors Another trend that could potentially confound the results of the current study is an increase in the intensity of diagnostic evaluation. 42 For example, if the rate of detection of lymph node metastases increased over time (either because of advances in technology or changes in clinical practice), then some cases of truly regional disease may have been mistakenly classified as localized in the earlier time periods. Relative survival would appear to increase over time as a result of this misclassification. We found that among both localized and regional breast carcinoma patients, the percentage of women who had any lymph nodes examined decreased slightly over time. Among those who had any lymph nodes examined, the average number of lymph nodes examined either decreased or remained stable. Because sentinel lymph node biopsy was not standard practice in the community by 1999, 43 it is an unlikely explanation for the decrease in lymph node sampling. Despite this slight decrease in axillary lymph node evaluation, we found that the proportion of regional tumors with lymph node involvement actually increased over time, from 84% in the cohort to 92% in the cohort. This suggests that the sensitivity of lymph node evaluation improved during this time period, and it is possible that this trend could have an impact on sizespecific survival. However, this concern applies to all analyses of survival trends, not just the innovation that we are proposing. A final caveat concerns the possible impact of length-biased sampling on the current results. Breast carcinoma cases that are screen-detected tend to involve slower-growing tumors, and therefore have longer survival, than cases that are not screen-detected. 12 For population-based analyses, length-biased sampling should have no effect on overall temporal comparisons of survival. However, because mammography rates have changed over time, length-biased sampling may affect the proportional allocation of cases to size categories, and therefore could have an unforeseen impact on size-standardization, although we suspect that this impact, if it exists at all, is likely to be minimal. Although we cannot isolate the effect of treatment advances on cancer survival, the results of the current analysis reveal differences in the magnitude of the tumor size-standardized increases in relative survival across age groups. Comparing the earliest and latest cohorts, the absolute difference in tumor size-standardized relative survival was found to be much greater in women younger than 65 years than in women age 65 years and older, in both stage categories. This suggests patient subgroups in which treatment has exerted its greatest impact. The results of the current study also reveal differences in size-standardized relative improvement across stage categories. Comparing the earliest and latest cohorts, the absolute difference in tumor sizestandardized relative survival was approximately 4 times as great in patients with regional breast carcinoma as in those with localized breast carcinoma (8.5% vs. 2.7%). However, the proportional reduction
8 1156 CANCER September 15, 2005 / Volume 104 / Number 6 in the percentage of breast carcinoma patients who did not survive for 5 years, absent other causes of death, (i.e., 1 minus size-standardized relative survival) was similar for localized and regional breast carcinoma patients. Understanding the impact of different cancer control strategies on disease outcomes in the population is a high priority for health policy decision makers. To this end, the National Cancer Institute established the Cancer Intervention and Surveillance Modeling Network (CISNET), a consortium of investigators developing complex, sophisticated computer models to simulate the effects of screening and treatment in the U.S. population, and thereby inform cancer control efforts and facilitate health care planning and resource allocation. 44 The current analysis shows that when evaluating temporal trends in case survival, stratification by tumor size can have a significant bearing on the interpretation of these trends. By comparing size-standardized survival statistics across cohorts, this method also provides a context for a more nuanced understanding of the reasons for age disparities in breast carcinoma outcomes. REFERENCES 1. Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, Bethesda, MD: National Cancer Institute, Chu KC, Tarone RE, Kessler LG, et al. Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst. 1996;88: National Institutes of Health/National Cancer Institute consensus development meeting on breast cancer screening: issues and recommendations. J Natl Cancer Inst. 1978;60: Breen N, Wagener DK, Brown ML, Davis WW, Ballard-Barbash R. Progress in cancer screening over a decade: results of cancer screening from the 1987, 1992, and 1998 National Health Interview Surveys. J Natl Cancer Inst. 2001;93: Early Breast Cancer Trialists Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352: Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998;351: Crown J. Evolution in the treatment of advanced breast cancer. Semin Oncol. 1998;25: Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J. Trends in the use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: J Natl Cancer Inst. 2002;94: Prorock PC, Kramer BS, Gohagan JK. Screening theory and study design: the basics. In: Kramer BS, Gohagan JK, Prorock PC, editors. Cancer screening: theory and practice. New York: Marcel Dekker, 1999: Feinleib M, Zelen M. Some pitfalls in the evaluation of screening programs. Arch Environ Health. 1969;19: Cole P, Morrison AS. Basic issues in population screening for cancer. J Natl Cancer Inst. 1980;64: Morrison AS. The effects of early treatment, lead time and length bias on the mortality experienced by cases detected by screening. Int J Epidemiol. 1982;11: Adami HO, Sparen P, Bergstrom R, Holmberg L, Krusemo UB, Ponten J. Increasing survival trend after cancer diagnosis in Sweden: J Natl Cancer Inst. 1989;81: Stockton D, Davies T, Day NE, McCann J. Retrospective study of reasons for improved survival in patients with breast cancer in East Anglia: earlier diagnosis or better treatment. BMJ. 1997;314: Brenner H, Stegmaier C, Ziegler H. Recent improvement in survival of breast cancer patients in Saarland, Germany. Br J Cancer. 1998;78: Ugnat AM, Xie L, Morriss J, Semenciw R, Mao Y. Survival of women with breast cancer in Ottawa, Canada: variation with age, stage, histology, grade and treatment. Br J Cancer. 2004; 90: Jemal A, Clegg L, Ward E, et al. Annual report to the nation on the status of cancer, , with a special feature regarding survival. Cancer. 2004;101: Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer: College of American Pathologists consensus statement Arch Pathol Lab Med. 2000;124: Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63: Rosenberg J, Chia YL, Plevritis S. The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the U.S. SEER database. Breast Cancer Res Treat. 2005;89: Hankey BF, Ries LA, Edwards BK. The Surveillance, Epidemiology, and End Results Program: a national resource. Cancer Epidemiol Biomarkers Prev. 1999;8: Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:IV Surveillance, Epidemiology, and End Results. SEER Program: comparative staging guide for cancer. Version 1.1. Bethesda, MD: National Institutes of Health, Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961;6: Surveillance, Epidemiology, and End Results. A guide to using SEER*Stat. Bethesda, MD: National Cancer Institute, Cancer Statistics Branch, Division of Cancer Control and Population Sciences, Hennekens CH, Buring JE. Epidemiology in medicine. Boston: Little, Brown and Company, Cochran WG. Some methods of strengthening the common X 2 tests. Biometrics. 1954;10: Armitage P. Tests for linear trends in proportions and frequencies. Biometrics. 1955;11: Duffy SW, Tabar L, Vitak B, et al. The relative contributions of screen-detected in situ and invasive breast carcinomas in reducing mortality from the disease. Eur J Cancer. 2003;39: McCarthy EP, Burns RB, Freunds KM, et al. Mammography use, breast cancer stage at diagnosis, and survival among older women. J Am Geriatr Soc. 2000;48: Michaelson JS, Satija S, Kopans D, et al. Gauging the impact of breast carcinoma screening in terms of tumor size and death rate. Cancer. 2003;98:
9 Tumor Size and Breast Ca Survival/Elkin et al Parker RG, Leung KM, Rees KS, Bassett LW, Legoretta AP. Mammographic screening downstages breast carcinomas at the time of diagnosis: a community-based experience. Breast J. 1999;5: Solin LJ, Legoretta AP, Schultz DJ, Zatz S, Goodman RL. The importance of mammographic screening relative to the treatment of women with carcinoma of the breast. Arch Intern Med. 1994;154: Solin LJ, Schultz DJ, Legoretta AP, Goodman RL. Downstaging of breast carcinomas in older women associated with mammographic screening. Breast J. 1999;5: Begg CB, Schrag D. Attribution of deaths following cancer treatment [editorial]. J Natl Cancer Inst. 2002;94: Brenner H, Hakulinen T. On crude and age-adjusted relative survival rates. J Clin Epidemiol. 2003;56: Brenner H, Arndt V, Gefeller O, Hakulinen T. An alternative approach to age adjustment of cancer survival rates. Eur J Cancer. 2004;40: Hoel DG, Ron E, Carter R, Mabuchi K. Influence of death certification errors on cancer mortality trends. J Natl Cancer Inst. 1993;85: Lloyd-Jones DM, Martin DO, Larson MG, Levy D. Accuracy of death certificates for coding coronary heart disease as the cause of death. Ann Intern Med. 1998;129: Ederer F, Geisser MS, Mongin SJ, Church TR, Mandel JS. Colorectal cancer deaths as determined by expert committee and from the death certificate: a comparison. The Minnesota study. J Clin Epidemiol. 1999;52: Lu TH, Shih TP, Lee MC, Chou MC, Lin CK. Diversity in death certification: a case vignette approach. J Clin Epidemiol. 2001;54: Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med. 1993;328: McMasters KM, Giuliano AE, Ross MI, et al. Sentinel-lymphnode biopsy for breast cancer not yet the standard of care. N Engl J Med. 1998;339: Boer R, Plevritis S, Clarke L. Diversity of model approaches: a review of model assumptions by the Cancer Intervention and Surveillance Network (CISNET) Breast Cancer Groups. Stat Methods Med Res. 2004;13:
Chapter 13 Cancer of the Female Breast
Lynn A. Gloeckler Ries and Milton P. Eisner INTRODUCTION This study presents survival analyses for female breast cancer based on 302,763 adult cases from the Surveillance, Epidemiology, and End Results
More informationAn Overview of Survival Statistics in SEER*Stat
An Overview of Survival Statistics in SEER*Stat National Cancer Institute SEER Program SEER s mission is to provide information on cancer statistics in an effort to reduce the burden of cancer among the
More informationThe projection of short- and long-term survival for. Conditional Survival Among Patients With Carcinoma of the Lung*
Conditional Survival Among Patients With Carcinoma of the Lung* Ray M. Merrill, PhD, MPH; Donald Earl Henson, MD; and Michael Barnes, PhD Objective: One- and 5-year probabilities of survival or death change
More informationAdjuvant Multi-agent Chemotherapy and Tamoxifen Usage Trends for Breast Cancer in the United States
Laboratory for Quantitative Medicine Technical Report #9 March 27, 29 Adjuvant Multi-agent Chemotherapy and Tamoxifen Usage Trends for Breast Cancer in the United States L. Leon Chen, BS 2 James S. Michaelson,
More informationBreast Cancer Trends Among Black and White Women in the United States Ismail Jatoi, William F. Anderson, Sowmya R. Rao, and Susan S.
VOLUME 23 NUMBER 31 NOVEMBER 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Breast Cancer Trends Among Black and White Women in the United States Ismail Jatoi, William F. Anderson, Sowmya
More informationAre Small Breast Cancers Good because They Are Small or Small because They Are Good?
The new england journal of medicine Special Report Are Small Breast Cancers Good because They Are Small or Small because They Are Good? Donald R. Lannin, M.D., and Shiyi Wang, M.D., Ph.D. The recent article
More informationRESEARCH ARTICLE. Comparison between Overall, Cause-specific, and Relative Survival Rates Based on Data from a Population-based Cancer Registry
DOI:http://dx.doi.org/.734/APJCP.22.3..568 RESEARCH ARTICLE Comparison between Overall, Cause-specific, and Relative Survival Rates Based on Data from a Population-based Cancer Registry Mai Utada *, Yuko
More informationOVER the past three decades, numerous randomized
Journal of Gerontology: MEDICAL SCIENCES 2005, Vol. 60A, No. 9, 1137 1144 Copyright 2005 by The Gerontological Society of America Effectiveness of Adjuvant for Node-Positive Operable Breast Cancer in Older
More informationQuantification of the effect of mammographic screening on fatal breast cancers: The Florence Programme
British Journal of Cancer (2002) 87, 65 69 All rights reserved 0007 0920/02 $25.00 www.bjcancer.com Quantification of the effect of mammographic screening on fatal breast cancers: The Florence Programme
More informationChapter 5: Epidemiology of MBC Challenges with Population-Based Statistics
Chapter 5: Epidemiology of MBC Challenges with Population-Based Statistics Musa Mayer 1 1 AdvancedBC.org, Abstract To advocate most effectively for a population of patients, they must be accurately described
More informationEstimated Minnesota Cancer Prevalence, January 1, MCSS Epidemiology Report 04:2. April 2004
MCSS Epidemiology Report 04:2 Suggested citation Perkins C, Bushhouse S.. Minnesota Cancer Surveillance System. Minneapolis, MN, http://www.health.state.mn.us/divs/hpcd/ cdee/mcss),. 1 Background Cancer
More informationAlthough African American women have a lower incidence of. Histologic Grade, Stage, and Survival in Breast Carcinoma
908 Histologic Grade, Stage, and Survival in Breast Carcinoma Comparison of African American and Caucasian Women Donald Earl Henson, M.D. 1 Kenneth C. Chu, Ph.D. 2 Paul H. Levine, M.D. 3 1 Department of
More informationEffect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
The new england journal of medicine original article Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer Donald A. Berry, Ph.D., Kathleen A. Cronin, Ph.D., Sylvia K. Plevritis, Ph.D.,
More informationLife expectancy in the United States continues to lengthen.
Reduced Mammographic Screening May Explain Declines in Breast Carcinoma in Older Women Robert M. Kaplan, PhD and Sidney L. Saltzstein, MD, MPH wz OBJECTIVES: To examine whether declines in breast cancer
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationTrends in Breast Cancer by Race and
Trends in Breast Cancer by Race and Ethnicity Trends in Breast Cancer by Race and Ethnicity Asma Ghafoor, MPH; Ahmedin Jemal, DVM, PhD; Elizabeth Ward, PhD; Vilma Cokkinides, PhD, MSPH; Robert Smith, PhD;
More informationNIH Public Access Author Manuscript Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2011 January 1.
NIH Public Access Author Manuscript Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2010 January ; 19(1): 144 147. doi:10.1158/1055-9965.epi-09-0807. Feasibility Study for Collection
More informationEffect of Three Decades of Screening Mammography on Breast-Cancer Incidence
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence Archie Bleyer, M.D., and H. Gilbert Welch, M.D., M.P.H.
More information6/20/2012. Co-authors. Background. Sociodemographic Predictors of Non-Receipt of Guidelines-Concordant Chemotherapy. Age 70 Years
Sociodemographic Predictors of Non-Receipt of Guidelines-Concordant Chemotherapy - among Locoregional Breast Cancer Patients Under Age 70 Years Xiao-Cheng Wu, MD, MPH 2012 NAACCR Annual Conference June
More informationCancer Programs Practice Profile Reports (CP 3 R) Rapid Quality Reporting System (RQRS)
O COLON MEASURE SPECIFICATIONS Cancer Programs Practice Profile Reports (CP 3 R) Rapid Quality Reporting System (RQRS) Introduction The Commission on Cancer s (CoC) National Cancer Data Base (NCDB) staff
More informationOncologist. The. Outcomes Research. Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period Analysis
The Oncologist Outcomes Research Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period Analysis DIANNE PULTE, a,b HERMANN BRENNER a a Division of Clinical Epidemiology
More informationR. A. Nout Æ W. E. Fiets Æ H. Struikmans Æ F. R. Rosendaal Æ H. Putter Æ J. W. R. Nortier
Breast Cancer Res Treat (2008) 109:567 572 DOI 10.1007/s10549-007-9681-x EPIDEMIOLOGY The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated
More informationThe Excess of Patients with Advanced Breast Cancer in Young Women Screened with Mammography in the Canadian National Breast Screening Study
997 The Excess of Patients with Advanced Breast Cancer in Young Women Screened with Mammography in the Canadian National Breast Screening Study Robert E. Tarone, Ph.D. Background. An unexpected excess
More informationImpact of PSA Screening on Prostate Cancer Incidence and Mortality in the US
Impact of PSA Screening on Prostate Cancer Incidence and Mortality in the US Deaths per 100,000 Ruth Etzioni Fred Hutchinson Cancer Research Center JASP Symposium, Montreal 2006 Prostate Cancer Incidence
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationPopulation Based Survival of Female Breast Cancer Cases in Riyadh Region, Saudi Arabia
RESEARCH COMMUNICATION Population Based Survival of Female Breast Cancer Cases in Riyadh Region, Saudi Arabia K Ravichandran 1, Nasser Al Hamdan 2, Abdul Rahman Al Dyab 3 Abstract Breast cancer is the
More informationLower-Category Benign Breast Disease and the Risk of Invasive Breast Cancer
Lower-Category Benign Breast Disease and the Risk of Invasive Breast Cancer Jiping Wang, Joseph P. Costantino, Elizabeth Tan-Chiu, D. Lawrence Wickerham, Soonmyung Paik, Norman Wolmark Background: The
More informationProphylactic Mastectomy
Prophylactic Mastectomy Policy Number: Original Effective Date: MM.06.010 01/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO 08/24/2012 Section: Surgery Place(s) of Service: Inpatient I.
More informationBreast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness
The new england journal of medicine Original Article Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness H. Gilbert Welch, M.D., M.P.H., Philip C. Prorok, Ph.D., A. James O
More informationIncidence cost estimates or longitudinal estimates of medical
CONDUCTING THE COST ANALYSIS Comparison of Approaches for Estimating Incidence Costs of Care for Colorectal Cancer Patients K. Robin Yabroff, PhD,* Joan L. Warren, PhD,* Deborah Schrag, MD, Angela Mariotto,
More informationPrediction of Lymph Node Involvement in Patients with Breast Tumors Measuring 3 5 cm in a Middle-Income Setting: the Role of CancerMath
DOI 10.1007/s00268-014-2752-3 BRIEF ORIGINAL SCIENTIFIC REPORT Prediction of Lymph Node Involvement in Patients with Breast Tumors Measuring 3 5 cm in a Middle-Income Setting: the Role of CancerMath E.
More informationUpdates on the Conflict of Postoperative Radiotherapy Impact on Survival of Young Women with Cancer Breast: A Retrospective Cohort Study
International Journal of Medical Research & Health Sciences Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(7): 14-18 I J M R
More informationHD RP. Breast cancer screening practices among American Indians and Alaska Natives in the Midwest
JOURNAL OF HD RP Journal of Health Disparities Research and Practice Volume 4, Number 3, Spring 2011, pp. 75-81 2011 Center for Health Disparities Research School of Community Health Sciences University
More informationGeneral principles of screening: A radiological perspective
General principles of screening: A radiological perspective Fergus Coakley MD, Professor and Chair, Diagnostic Radiology, Oregon Health and Science University General principles of screening: A radiological
More informationConditional survival after a diagnosis of malignant brain tumour in Canada:
ORIGINAL ARTICLE BRAIN CANCER CONDITIONAL SURVIVAL PROBABILITIES: 2000 2008, Yuan et al. Conditional survival after a diagnosis of malignant brain tumour in Canada: 2000 2008 Y. Yuan phd,* J. Ross mph,*
More informationORIGINAL INVESTIGATION. Effect of a Dementia Diagnosis on Survival of Older Patients After a Diagnosis of Breast, Colon, or Prostate Cancer
ORIGINAL INVESTIGATION Effect of a Dementia Diagnosis on Survival of Older Patients After a Diagnosis of Breast, Colon, or Prostate Cancer Implications for Cancer Care Mukaila A. Raji, MD, MSc; Yong-Fang
More informationAdjuvant Chemotherapy for Patients with Stage III Colon Cancer: Results from a CDC-NPCR Patterns of Care Study
COLON CANCER ORIGINAL RESEARCH Adjuvant Chemotherapy for Patients with Stage III Colon Cancer: Results from a CDC-NPCR Patterns of Care Study Rosemary D. Cress 1, Susan A. Sabatino 2, Xiao-Cheng Wu 3,
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationSources of Black-White Differences in Cancer Screening and Mortality
Sources of Black-White Differences in Cancer Screening and Mortality Abstract In 1971, President Nixon initiated the war on cancer, which led to dramatic increases in spending on cancer research and treatment.
More informationUsing Surveillance Epidemiology and End Results data to explore breast cancer mortality trend in an underserved population of Alabama, USA
20th International Congress on Modelling and Simulation, Adelaide, Australia, 1 6 December 2013 www.mssanz.org.au/modsim2013 Using Surveillance Epidemiology and End Results data to explore breast cancer
More informationVariation of Benefits and Harms of Breast Cancer Screening With Age
Variation of Benefits and Harms of Breast Cancer Screening With Age Russell Harris* The critical issue in deciding whether to recommend breast cancer screening for women in their forties is to determine
More informationDiabetes and Decline in Heart Disease Mortality in US Adults JAMA. 1999;281:
ORIGINAL CONTRIBUTION and Decline in Mortality in US Adults Ken Gu, PhD Catherine C. Cowie, PhD, MPH Maureen I. Harris, PhD, MPH MORTALITY FROM HEART disease has declined substantially in the United States
More informationTrends in Cancer Survival in NSW 1980 to 1996
Trends in Cancer Survival in NSW 19 to 1996 Xue Q Yu Dianne O Connell Bruce Armstrong Robert Gibberd Cancer Epidemiology Research Unit Cancer Research and Registers Division The Cancer Council NSW August
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationProphylactic Mastectomy State of the Art
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 6 th Brazilian Breast Cancer Conference Sao Paulo, Brazil 9 March 2012 Prophylactic Mastectomy State of the Art Monica Morrow
More informationCancer Screening: Evidence, Opinion and Fact Dialogue on Cancer April Ruth Etzioni Fred Hutchinson Cancer Research Center
Cancer Screening: Evidence, Opinion and Fact Dialogue on Cancer April 2018? Ruth Etzioni Fred Hutchinson Cancer Research Center Three thoughts to begin 1. Cancer screening is a good idea in principle Detect
More informationNIH Public Access Author Manuscript Cancer. Author manuscript; available in PMC 2006 December 17.
NIH Public Access Author Manuscript Published in final edited form as: Cancer. 2005 December 15; 104(12 Suppl): 2989 2998. 1999 2001 Cancer Mortality Rates for Asian and Pacific Islander Ethnic Groups
More informationEffect of NHS breast screening programme on mortality from breast cancer in England and Wales, : comparison of observed with predicted mortality
Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality R G Blanks, S M Moss, C E McGahan, M J Quinn, P J
More informationTalk to Your Doctor. Fact Sheet
Talk to Your Doctor Hearing the words you have skin cancer is overwhelming and would leave anyone with a lot of questions. If you have been diagnosed with Stage I or II cutaneous melanoma with no apparent
More informationBREAST CANCER IN IDAHO
BREAST CANCER IN IDAHO 1997-2001 1 2 3 4 5 7 6 Non-Hospital Mammography Facilities Idaho Hospitals Health Districts Idaho County Boundaries This PowerPoint presentation was created as a collaborative effort
More informationChapter 23 Cancer of the Urinary Bladder
Charles F. Lynch, Jessica A. Davila, and Charles E. Platz Introduction Cancer of the urinary bladder most commonly originates in the urothelium, the epithelium that lines the bladder. During 6, this is
More informationThe TNM classification is a worldwide benchmark for reporting the
1 COMMENTARY The Process for Continuous Improvement of the TNM Classification Mary K. Gospodarowicz, M.D. 1 Daniel Miller, M.D., M.P.H. 2 Patti A. Groome, M.Sc., Ph.D. 3 Frederick L. Greene, M.D. 4 Pamela
More informationLife Expectancy of Screen-Detected Invasive Breast Cancer Patients Compared With Women Invited to the Nijmegen Screening Program
Original Article Life Expectancy of Screen-Detected Invasive Breast Cancer Patients Compared With Women Invited to the Nijmegen Screening Program Johannes D. M. Otten 1,2 ; Mireille J. M. Broeders 1,2,3
More informationReport on Cancer Statistics in Alberta. Breast Cancer
Report on Cancer Statistics in Alberta Breast Cancer November 2009 Surveillance - Cancer Bureau Health Promotion, Disease and Injury Prevention Report on Cancer Statistics in Alberta - 2 Purpose of the
More informationIntroduction. Wilfred Truin 1 Rudi M. H. Roumen. Vivianne C. G. Tjan-Heijnen 2 Adri C. Voogd
Breast Cancer Res Treat (2017) 164:133 138 DOI 10.1007/s10549-017-4220-x EPIDEMIOLOGY Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients
More informationLifetime Risk of Cardiovascular Disease Among Individuals with and without Diabetes Stratified by Obesity Status in The Framingham Heart Study
Diabetes Care Publish Ahead of Print, published online May 5, 2008 Lifetime Risk of Cardiovascular Disease Among Individuals with and without Diabetes Stratified by Obesity Status in The Framingham Heart
More informationPeriod estimates of cancer patient survival are more up-to-date than complete estimates even at comparable levels of precision
Journal of Clinical Epidemiology 59 (2006) 570 575 ORIGINAL ARTICLES Period estimates of cancer patient survival are more up-to-date than estimates even at comparable levels of precision Hermann Brenner
More informationShe counts on your breast cancer expertise at the most vulnerable time of her life.
HOME She counts on your breast cancer expertise at the most vulnerable time of her life. Empowering the right treatment choice for better patient outcomes. The comprehensive genomic assay experts trust.
More informationBREAST MRI. Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School
BREAST MRI Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School BREAST MRI Any assessment of the breast parenchyma requires the administration
More informationChanging Incidence of Hodgkin Lymphoma Histologic Subtypes: Risk Factor Trends or Evolving Diagnostic Practice?
Changing Incidence of Hodgkin Lymphoma Histologic Subtypes: Risk Factor Trends or Evolving Diagnostic Practice? Greater Bay Area Cancer Registry Cancer Prevention Institute of California Stanford Cancer
More informationIncreasing the number of older persons in the United
Current Capacity for Endoscopic Colorectal Cancer Screening in the United States: Data from the National Cancer Institute Survey of Colorectal Cancer Screening Practices Martin L. Brown, PhD, Carrie N.
More informationColorectal Cancer Report on Cancer Statistics in Alberta. December Cancer Care. Cancer Surveillance
December 212 21 Acknowledgements 2 This report was made possible through Alberta Health Services,, and the many contributions of staff and management across Alberta Health Services as well as external
More informationImproved Prognosis of Women Aged 75 and Older with Mammography-detected Breast Cancer 1
Note: This copy is for your personal non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights. Original Research
More informationTHE ISSUE OF STAGE AT DIAGNOSIS
THE ISSUE OF STAGE AT DIAGNOSIS IN SURVIVAL ANALYSIS Pamela Minicozzi Analytical Epidemiology and Health Impact Unit Department of Preventive and Predictive Medicine, Fodazione IRCCS Istituto Nazionale
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationAccelerating Innovation in Statistical Design
Implementing a National Cancer Clinical Trials System for the 21 st Century, Workshop #2 Session #5: Accelerating Innovation Through Effective Partnerships Accelerating Innovation in Statistical Design
More informationProblems in staging breast carcinoma
Problems in staging breast carcinoma Primary systemic therapy (PST) of breast carcinoma pathologists tasks Dr. Janina Kulka, 2nd Department of Pathology, Semmelweis University Budapest Austro-Hungarian
More informationRelative dose intensity delivered to patients with early breast cancer: Canadian experience
M E D I C A L O N C O L O G Y Relative dose intensity delivered to patients with early breast cancer: Canadian experience S. Raza MD, S. Welch MD, and J. Younus MD ABSTRACT Adjuvant chemotherapy for early
More informationSummary of the BreastScreen Aotearoa Mortality Evaluation
Summary of the BreastScreen Aotearoa Mortality Evaluation 1999 2011 Released 2015 nsu.govt.nz Citation: Ministry of Health. 2015. Summary of the BreastScreen Aotearoa Mortality Evaluation 1999 2011. Wellington:
More informationAndrogen deprivation therapy for treatment of localized prostate cancer and risk of
Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies Lauren P. Wallner, Renyi Wang, Steven J. Jacobsen, Reina Haque Department of Research and
More informationPosition Statement on Management of the Axilla in Patients with Invasive Breast Cancer
- Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the
More informationLong-term survival of cancer patients in Germany achieved by the beginning of the third millenium
Original article Annals of Oncology 16: 981 986, 2005 doi:10.1093/annonc/mdi186 Published online 22 April 2005 Long-term survival of cancer patients in Germany achieved by the beginning of the third millenium
More informationReport on Cancer Statistics in Alberta. Melanoma of the Skin
Report on Cancer Statistics in Alberta Melanoma of the Skin November 29 Surveillance - Cancer Bureau Health Promotion, Disease and Injury Prevention Report on Cancer Statistics in Alberta - 2 Purpose of
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More information4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines
SEER EOD and Summary Stage KCR 2018 SPRING TRAINING Overview What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets SEER Summary Stage 2018 Site Specific
More informationEstimating and modelling relative survival
Estimating and modelling relative survival Paul W. Dickman Department of Medical Epidemiology and Biostatistics Karolinska Institutet, Stockholm, Sweden paul.dickman@ki.se Regstat 2009 Workshop on Statistical
More informationFinancial Disclosure. Learning Objectives. Review and Impact of the NCDB PUF. Moderator: Sandra Wong, MD, MS, FACS, FASCO
Review and Impact of the NCDB PUF Moderator: Sandra Wong, MD, MS, FACS, FASCO Financial Disclosure I do not have personal financial relationships with any commercial interests Learning Objectives At the
More informationEthnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer. Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD,
Ethnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD, MD, Paul Hebert, PhD, Michael C. Iannuzzi, MD, and
More informationGeographic Variations in Breast Cancer Survival Among Older Women: Implications for Quality of Breast Cancer Care
Journal of Gerontology: MEDICAL SCIENCES 2002, Vol. 57A, No. 6, M401 M406 Copyright 2002 by The Gerontological Society of America Geographic Variations in Breast Cancer Survival Among Older Women: Implications
More information7/29/2014. FCDS Annual Meeting July 24-25, 2014 Caribe Royale Resort Orlando, Florida
FCDS Annual Meeting July 24-25, 2014 Caribe Royale Resort Orlando, Florida Data collected by central cancer registries is utilized for patient outcomes research Requires complete detailed treatment data
More informationSetting The setting was not clear. The economic study was carried out in the USA.
Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis Das P, Ng A K, Earle C C, Mauch P M, Kuntz K M Record Status This is a critical
More informationLinking Oncotype Dx results to SEER data and patient report to assess challenges in individualizing breast cancer care
Linking Oncotype Dx results to SEER data and patient report to assess challenges in individualizing breast cancer care June 16, 2015 NAACCR, Charlotte, NC Ann Hamilton, Ph.D. Keck School of Medicine, University
More informationORIGINAL ARTICLE. US Mortality Rates for Oral Cavity and Pharyngeal Cancer by Educational Attainment
ORIGINAL ARTICLE US Mortality Rates for Oral Cavity and Pharyngeal Cancer by Educational Attainment Amy Y. Chen, MD, MPH; Carol DeSantis, MPH; Ahmedin Jemal, PhD Objective: To describe trends in mortality
More informationA DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY. Helen Mari Parsons
A Culture of Quality? Lymph Node Evaluation for Colon Cancer Care A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY Helen Mari Parsons IN PARTIAL FULFILLMENT
More informationProphylactic Mastectomy
Prophylactic Mastectomy Policy Number: Original Effective Date: MM.06.010 01/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO 07/22/2011 Section: Surgery Place(s) of Service: Inpatient I.
More informationRACIAL DISPARITIES AND TRENDS IN RADIATION THERAPY AFTER BREAST-CONSERVING SURGERY FOR EARLY-STAGE BREAST CANCER IN WOMEN, 1992 TO 2002
RACIAL DISPARITIES AND TRENDS IN RADIATION THERAPY AFTER BREAST-CONSERVING SURGERY FOR EARLY-STAGE BREAST CANCER IN WOMEN, 1992 TO 2002 Objectives: Clinical guidelines recommend that when breast-conserving
More informationarticle MATERIALS AND METHODS
September 2006 Vol. 8 No. 9 article Population-based study of the prevalence of family history of cancer: Implications for cancer screening and prevention Scott D. Ramsey, MD, PhD 1,2, Paula Yoon, ScD,
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationThe Linked SEER-Medicare Data and Cancer Effectiveness Research
The Linked SEER-Medicare Data and Cancer Effectiveness Research Arnold L. Potosky, PhD Professor of Oncology Director of Health Services Research Georgetown University Medical Center Lombardi Comprehensive
More informationDAYS IN PANCREATIC CANCER
HOSPITAL AND MEDICAL CARE DAYS IN PANCREATIC CANCER Annals of Surgical Oncology, March 27, 2012 Casey B. Duncan, Kristin M. Sheffield, Daniel W. Branch, Yimei Han, Yong-Fang g Kuo, James S. Goodwin, Taylor
More informationOriginal Policy Date
MP 7.01.06 Prophylactic Mastectomy Medical Policy Section Surgery Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical Policy Index
More informationTime intervals for isolated care steps in the diagnosis
Research Recherche Elapsed time from breast cancer detection to first adjuvant therapy in a Canadian province, 1999 2000 Daniel Rayson, Darrell Chiasson, Ron Dewar DOI:10.1053/cmaj.1020972 Abstract Background:
More informationDecline and Disparities in Mammography Use Trends by Socioeconomic Status and Race/Ethnicity
244 Decline and Disparities in Mammography Use Trends by Socioeconomic Status and Race/Ethnicity Kanokphan Rattanawatkul Mentor: Dr. Olivia Carter-Pokras, Associate Professor Department of Epidemiology
More informationPredicting the Survival of Patients with Breast Carcinoma using Tumor Size
713 Predicting the Survival of Patients with Breast Carcinoma using Tumor Size James S. Michaelson, Ph.D. 1 4 Melvin Silverstein, M.D. 5 John Wyatt, Ph.D. 6 Griffin Weber, B.A., B.S. 2 Richard Moore, B.A.
More information2012 Report on Cancer Statistics in Alberta
212 Report on Cancer Statistics in Alberta Kidney Cancer Surveillance & Reporting CancerControl AB February 215 Acknowledgements This report was made possible through Surveillance & Reporting, Cancer Measurement
More informationThe National Accreditation Program for Breast Centers American Program Considerations. Maurício Magalhães Costa Cary S. Kaufman February 9, 2012
The National Accreditation Program for Breast Centers American Program Considerations Maurício Magalhães Costa Cary S. Kaufman February 9, 2012 Disclosure I HAVE NO COMMERCIAL INTEREST TO REPORT NAPBC
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/55957 holds various files of this Leiden University dissertation Author: Dekker T.J.A. Title: Optimizing breast cancer survival models based on conventional
More informationCancer Programs Practice Profile Reports (CP 3 R) Rapid Quality Reporting System (RQRS)
MEASURE SPECIFICATIOS Cancer Programs Practice Profile Reports (CP 3 R) Rapid Quality Reporting System (RQRS) Introduction The Commission on Cancer s (CoC) ational Cancer Data Base (CDB) staff has undertaken
More informationHealth Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015
Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015 Outline Epidemiology of prostate cancer Purpose of screening Method of screening Contemporary screening trials
More informationCreating prognostic systems for cancer patients: A demonstration using breast cancer
Received: 16 April 2018 Revised: 31 May 2018 DOI: 10.1002/cam4.1629 Accepted: 1 June 2018 ORIGINAL RESEARCH Creating prognostic systems for cancer patients: A demonstration using breast cancer Mathew T.
More information